Tag Archives: Compliance

Digital Health Startup Alyve Health Secures $6M in Series A Funding Round and Additional News Briefs

Digital Health Startup Alyve Health Secures $6M in Series A Funding Round and Additional News Briefs

Alyve Health, an emerging player in the Indian digital health market, recently secured a substantial $5.5 million in Series A financing. This funding round was led by Axilor Ventures and saw participation from 1Crowd Fund, InHealth Ventures, and Trifecta Capital. Since its inception in 2020, Alyve Health has been on a mission to revolutionize personalized […]

Continue Reading

FDA Releases Draft Guidance on Action Plans for Increasing Diversity in Clinical Trials

FDA Releases Draft Guidance on Action Plans for Increasing Diversity in Clinical Trials

The Food and Drug Administration (FDA) recently released a draft guidance aiming to improve the diversity of participants in clinical trials by establishing a framework for diversity action plans. This initiative, prompted by legislation passed by Congress in 2022, mandates that drug and device makers submit these plans to the FDA. The legislation set a […]

Continue Reading

House Committee Votes on Including Obesity Drugs in Medicare Coverage

House Committee Votes on Including Obesity Drugs in Medicare Coverage

On Thursday, the House Ways & Means Committee moved forward with four significant pieces of legislation aimed at enhancing Medicare coverage and modifying certain regulatory frameworks. These bills, passed with robust bipartisan support, address the inclusion of obesity drugs and cancer screening tests under Medicare and implement changes concerning Medicare’s discretion in the coverage of […]

Continue Reading

Medicare Announces Reimbursement Rule for Breakthrough Devices Expected by Summer

Medicare Announces Reimbursement Rule for Breakthrough Devices Expected by Summer

In Washington, there are ongoing developments concerning a federal rule that intends to simplify the reimbursement process for breakthrough medical devices. This rule is anticipated to be finalized early this summer according to Dora Hughes, the director of the clinical standards center at the Centers for Medicare and Medicaid Services (CMS). Hughes communicated this timeline […]

Continue Reading

Novo Nordisk’s Medication Unsuccessful in Crucial Trial for Hypertension and Chronic Kidney Disease

Novo Nordisk’s Medication Unsuccessful in Crucial Trial for Hypertension and Chronic Kidney Disease

A key investigational drug from Novo Nordisk, intended for the treatment of hypertension and chronic kidney disease, has failed to meet its goals in a critical Phase 3 trial. This outcome has consequently hindered the Danish pharmaceutical company’s ambitions to offer a new treatment alternative that hoped to surpass the safety and efficacy of existing […]

Continue Reading

Peter Marks from CBER Discusses New Rare Disease Hub and Upcoming Guidance on Accelerated Approvals: An Exclusive Analysis in Life Science

Peter Marks from CBER Discusses New Rare Disease Hub and Upcoming Guidance on Accelerated Approvals: An Exclusive Analysis in Life Science

I’m sorry, but I’m unable to provide a summary for the content as there isn’t enough detailed information available in your request to summarize it to 800 words. The text provided mentions Peter Marks, director of FDA’s Center for Biologics Evaluation and Research (CBER), speaking at the Drug Information Association (DIA) annual meeting about a […]

Continue Reading

Unlocking Market Adoption: The Essential Guide

Unlocking Market Adoption: The Essential Guide

In a critical discussion on the Global Medical Device Podcast, hosted by Etienne Nichols, Shaherah Yancy, CEO of Research Lifecycle Solutions, shared her profound insights on key strategies for MedTech companies, particularly focusing on the importance of clinical and regulatory frameworks. Here’s a breakdown of their conversation and the valuable takeaways for anyone involved in […]

Continue Reading